The global health body, in a document released on Epilepsy Day today, said around 50 million people worldwide have epilepsy. About three-fourth of those with this condition living in low and middle-income countries like India do not get the care they need due to what is called "treatment gap".
"In both China and India, epilepsy is commonly viewed as a reason for prohibiting or annulling marriages," the World Health Organisation said, adding people with this condition respond to treatment approximately 70 per cent of the time.
"A recent study found the average availability of generic anti-epileptic medicines in the public sector of low and middle-income countries to be less than 50 per cent. This may act as a barrier to accessing treatment," it said.
WHO said an Indian study conducted in 1998 calculated that the cost of epilepsy treatment per patient was as high as 88.2 per cent of the country's per capita Gross National Product (GNP) and epilepsy-related costs, which included medical, travel expenditure and lost work time exceeded $2.6 billion per year.
Approximately 50 million people currently suffer from epilepsy worldwide. The estimated proportion of the general population with active epilepsy at a given time is between 4 and 10 per 1,000 people, the global health body said.
"However, some studies in low and middle-income countries suggest that the proportion is much higher, between 7 and 14 per 1,000 people. Globally, an estimated 2.4 million people are diagnosed with epilepsy each year.
problems (such as fractures and bruising from injuries related to it), as well as higher rates of psychological conditions, including anxiety and depression.
"Similarly, the risk of premature death in people with epilepsy is up to three times higher than the general population, with the highest rates found in low and middle-income countries and rural versus urban areas," it said.
A great proportion of the causes of death related to epilepsy in low and middle-income countries, such as falls, drowning, burns and prolonged seizures, are potentially preventable, the WHO said.
"Recent studies in both low and middle-income countries have shown that up to 70 per cent of children and adults with epilepsy can be successfully treated (their seizures completely controlled) with anti-epileptic drugs.
"Furthermore, after two to five years of successful treatment and being seizure-free, drugs can be withdrawn in about 70 per cent of children and 60 per cent of adults without subsequent relapse," the WHO said.
Epilepsy accounts for 0.6 per cent of the global burden of diseases, a time-based measure that combines years of life lost due to premature mortality and time lived in less than full health.
As an initiative set up in 1997, WHO, the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) are carrying out a global campaign - 'Out of the Shadows' - to provide better information, raise awareness about epilepsy and strengthen public and private efforts to improve care and reduce the disorder's impact.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
